{
    "clinical_study": {
        "@rank": "63825", 
        "brief_summary": {
            "textblock": "This non-interventional, observational study evaluates the efficacy of Targinact with regard\n      to pain relief in daily clinical practice in Belgium compared to the previous analgesic\n      treatment."
        }, 
        "brief_title": "A Non-interventional, Observational Study for Targinact\u00ae Treatment in Patients With Severe Pain.", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Severe Pain", 
        "detailed_description": {
            "textblock": "Patients are treated with Targinact\u00ae according to daily clinical practice and are monitored\n      during 3 study visits. Parameters assessed are efficacy regarding pain relief, efficacy\n      regarding bowel function, pain relief, use of analgesic rescue medication, bowel function,\n      use of laxatives, safety of Targinact treatment, use of concomitant medication, patient\n      satisfaction and quality of life."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n        Patients who are to be included in the study, are those who meet all of the following\n        criteria based on the SPC.\n\n          1. Male or female patients at least 18 years, or older, with severe pain.\n\n          2. Patients with documented history of severe pain treated with WHO step 1, step 2\n             and/or 3 analgesics with insufficient pain relief and/or unacceptable side effects\n             that require around-the-clock opioid therapy and are likely to benefit from WHO step\n             3 opioid therapy for the duration of the study.\n\n        Exclusion criteria are based on the SPC of Targinact\u00ae."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "GPs and specialists"
            }
        }, 
        "enrollment": {
            "#text": "1338", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01983137", 
            "org_study_id": "OXN9510"
        }, 
        "intervention": {
            "intervention_name": "Targinact\u00ae (oxycodone/naloxone)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Analgesics", 
                "Oxycodone", 
                "Naloxone"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Chronic pain", 
            "Severe pain", 
            "oxycodon", 
            "naloxon", 
            "opioid-induced constipation", 
            "opioid", 
            "quality of life", 
            "laxative", 
            "analgesic rescue medication"
        ], 
        "lastchanged_date": "November 6, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Antwerp", 
                    "country": "Belgium"
                }, 
                "name": "University Hospital Antwerp (UZA):"
            }
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_groups": "1", 
        "official_title": "The Efficacy, With Regard to Pain Relief, of Targinact\u00ae Treatment for Patients With Severe Pain Compared to Previous Analgesic Treatment; a Non-interventional Study.", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium:Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten (FAGG)", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Efficacy will be evaluated by the physician (7 categories). For the analysis the ordinal scale will be reduced to a binary scale: responder or non-responder. A responder is defined as a patient responding ''slightly better'',  ''better'' or ''much better'' at any time during the Targinact\u00aetherapy.  A non-responder is defined as a patient responding \"same\", \"slightly worse\", \"worse\", \"much worse\".", 
            "measure": "To evaluate  the efficacy of Targinact\u00ae treatment, with regard to pain relief, in patients with severe pain", 
            "safety_issue": "No", 
            "time_frame": "Up to 140 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01983137"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The relative changes from baseline at each visit will be used to compare the NAS pain scores during the Targinact\u00ae therapy.", 
                "measure": "Pain NAS score (0-10) will be measured at each visit", 
                "safety_issue": "No", 
                "time_frame": "Up to 140 days"
            }, 
            {
                "description": "The Bowel Function Index is the mean value of the 3 single items included in the BFI:1/ Difficulty of bowel movement (0 to 100; 0 = easy/no difficulty, 100 = severe difficulty); 2/ Feeling of incomplete bowel evacuation (0 to 100; 0 = not at all, 100 = very strong); 3/ Judgement of constipation (0 to 100; 0 = not at all, 100 = very strong).", 
                "measure": "Bowel Function Index (BFI) will be recorded  at each visit", 
                "safety_issue": "No", 
                "time_frame": "Up to 140 days"
            }, 
            {
                "description": "If laxative is used, the physician will document if it's used 1/ continuously, 2/ intermittently or 3/ rarely.", 
                "measure": "The use of laxative medication (yes/no) per 24 hours will be recorded in the e-CRF", 
                "safety_issue": "No", 
                "time_frame": "Up to 140 days"
            }, 
            {
                "measure": "The use of analgesic  rescue medication (yes/no) used per day (24 hours) will be recorded", 
                "safety_issue": "No", 
                "time_frame": "Up to 140 days"
            }, 
            {
                "description": "For the analysis the ordinal scale will be reduced to a binary scale: responder or non-responder. A responder is defined as a patient responding ''slightly better'',  ''better'' or ''much better'' at any time during the Targinact\u00ae therapy.  A non-responder is defined as a patient responding \"same\", \"slightly worse\", \"worse\", \"much worse\".", 
                "measure": "Efficacy of Targinact\u00ae treatment, with regard to bowel function, will be evaluated by the physician (7 categories)", 
                "safety_issue": "No", 
                "time_frame": "Up to 140 days"
            }, 
            {
                "description": "much worse, worse, slightly worse, same, slightly better, better, much better.", 
                "measure": "The patient satisfaction will be evaluated by patient in 7 categories", 
                "safety_issue": "No", 
                "time_frame": "Up to 140 days"
            }, 
            {
                "measure": "The patient's quality of life will be evaluated via the EQ-5D questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Up to 140 days"
            }
        ], 
        "source": "Mundipharma CVA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mundipharma CVA", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2011", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}